Ovid Therapeutics sold ganaxolone royalty rights to Immedica, which subsequently acquired Ovid's IP portfolio and completed the acquisition of Marinus.
2 reports, 1 independent
Updated Jul 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ovid Therapeutics sold ganaxolone royalty rights to Immedica, which subsequently acquired Ovid's IP portfolio and completed the acquisition of Marinus.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ovid Therapeutics (United States)
company in New York, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyOvid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics an
- Unknown outlet